Patents by Inventor Stefan GRATHWOHL

Stefan GRATHWOHL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS FOR USE IN THE TREATMENT OF MICROGLIA-MEDIATED DISORDERS
    Publication number: 20250213538
    Abstract: Provided are M1 muscarinic acetylcholine receptor (mAChR) agonists, for use in the treatment of a neurological or neurodegenerative disease by promoting microglia and/or macrophage viability and/or activation. Microglia and macrophage survival and activation are thereby achieved by increasing levels of sTREM2 released by microglia cells. In addition, pharmaceutical compositions and methods of preparing the same are described, which are suitable for the treatment or prevention of conditions or diseases that require microglia and/or macrophage modulation, as well as methods for monitoring treatments and enhancing microglia and/or macrophage survival and/or activation.
    Type: Application
    Filed: December 10, 2024
    Publication date: July 3, 2025
    Inventors: Abraham FISHER, Stefan GRATHWOHL, Roger NITSCH
  • Compounds and methods for use in the treatment of microglia-mediated disorders
    Patent number: 12201619
    Abstract: Provided are M1 muscarinic acetylcholine receptor (mAChR) agonists, for use in the treatment of a neurological or neurodegenerative disease by promoting microglia and/or macrophage viability and/or activation. Microglia and macrophage survival and activation are thereby achieved by increasing levels of sTREM2 released by microglia cells. In addition, pharmaceutical compositions and methods of preparing the same are described, which are suitable for the treatment or prevention of conditions or diseases that require microglia and/or macrophage modulation, as well as methods for monitoring treatments and enhancing microglia and/or macrophage survival and/or activation.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: January 21, 2025
    Assignee: NSC Therapeutics GmbH
    Inventors: Abraham Fisher, Stefan Grathwohl, Roger Nitsch
  • COMPOUNDS AND METHODS FOR USE IN THE TREATMENT OF MICROGLIA-MEDIATED DISORDERS
    Publication number: 20210000807
    Abstract: Provided are M1 muscarinic acetylcholine receptor (mAChR) agonists, for use in the treatment of a neurological or neurodegenerative disease by promoting microglia and/or macrophage viability and/or activation. Microglia and macrophage survival and activation are thereby achieved by increasing levels of sTREM2 released by microglia cells. In addition, pharmaceutical compositions and methods of preparing the same are described, which are suitable for the treatment or prevention of conditions or diseases that require microglia and/or macrophage modulation, as well as methods for monitoring treatments and enhancing microglia and/or macrophage survival and/or activation.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 7, 2021
    Inventors: Abraham FISHER, Stefan GRATHWOHL, Roger NITSCH